Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for EGFR-mutated non-small-cell lung cancer, drawn from the whole corpus: 103 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No head-to-head trial compares the three first-line strategies, and the added toxicity of the combinations falls on every patient for a benefit concentrated in some.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Most resistance to osimertinib has no identifiable mechanism and no targeted option.
Background: Drug resistance (primary and acquired), EGFR C797S, Histologic transformation, MET amplification (bypass resistance). Also on OnCo: Resistance atlas · Lines of therapy.
Whether adjuvant osimertinib cures more patients or delays recurrence beyond the three years of treatment is still being followed.
Nothing recorded yet.
Background: Neoadjuvant / adjuvant / perioperative. Also on OnCo: Treatment journeys · Survivorship planner.
Checkpoint inhibitors add little and increase pneumonitis when combined with EGFR inhibitors.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 20 changes by month →When this page itself was last checked or edited.
PFS HR 0.
A milestone in how this cancer is treated.
PFS HR 0.
A milestone in how this cancer is treated.
PFS HR 0.